The association of RP-ILD with anti-MDA5 antibody levels and anti-Ro52 antibody status in CADM patients
Anti-MDA5 antibody levels . | Anti-Ro52 antibody status . | RP-ILD, % (n) . | P-value . |
---|---|---|---|
Weak (+) | Positive (n = 4) | 25.0 (1) | 1.000 |
Negative (n = 3) | 33.3 (1) | ||
Moderate (++) | Positive (n = 17) | 64.7 (11) | 0.030 |
Negative (n = 8) | 12.5 (1) | ||
Strong (+++) | Positive (n = 41) | 53.7 (22) | 0.291 |
Negative (n = 10) | 30 (3) |
Anti-MDA5 antibody levels . | Anti-Ro52 antibody status . | RP-ILD, % (n) . | P-value . |
---|---|---|---|
Weak (+) | Positive (n = 4) | 25.0 (1) | 1.000 |
Negative (n = 3) | 33.3 (1) | ||
Moderate (++) | Positive (n = 17) | 64.7 (11) | 0.030 |
Negative (n = 8) | 12.5 (1) | ||
Strong (+++) | Positive (n = 41) | 53.7 (22) | 0.291 |
Negative (n = 10) | 30 (3) |
The chi-squared or Fisher’s exact test was used to compare categorical variables.
The association of RP-ILD with anti-MDA5 antibody levels and anti-Ro52 antibody status in CADM patients
Anti-MDA5 antibody levels . | Anti-Ro52 antibody status . | RP-ILD, % (n) . | P-value . |
---|---|---|---|
Weak (+) | Positive (n = 4) | 25.0 (1) | 1.000 |
Negative (n = 3) | 33.3 (1) | ||
Moderate (++) | Positive (n = 17) | 64.7 (11) | 0.030 |
Negative (n = 8) | 12.5 (1) | ||
Strong (+++) | Positive (n = 41) | 53.7 (22) | 0.291 |
Negative (n = 10) | 30 (3) |
Anti-MDA5 antibody levels . | Anti-Ro52 antibody status . | RP-ILD, % (n) . | P-value . |
---|---|---|---|
Weak (+) | Positive (n = 4) | 25.0 (1) | 1.000 |
Negative (n = 3) | 33.3 (1) | ||
Moderate (++) | Positive (n = 17) | 64.7 (11) | 0.030 |
Negative (n = 8) | 12.5 (1) | ||
Strong (+++) | Positive (n = 41) | 53.7 (22) | 0.291 |
Negative (n = 10) | 30 (3) |
The chi-squared or Fisher’s exact test was used to compare categorical variables.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.